Over 137 million US adults are eligible for semaglutide, driven by expanding indications for diabetes, weight management, and cardiovascular disease prevention.
More than half of all US adults are eligible for semaglutide therapy
- Post author:
- Post published:November 20, 2024
- Post category:uncategorized